Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CPI-1205 |
Synonyms | |
Therapy Description |
CPI-1205 inhibits EZH2, including both wild-type and mutant forms, potentially resulting in decreased tumor growth (PMID: 27739677, PMID: 29905573). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CPI-1205 | EZH2 inhibitor 20 | CPI-1205 inhibits EZH2, including both wild-type and mutant forms, potentially resulting in decreased tumor growth (PMID: 27739677, PMID: 29905573). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ARID1A dec exp | urinary bladder cancer | sensitive | CPI-1205 | Preclinical - Cell culture | Actionable | In a preclinical study, CPI-1205 inhibited viability of bladder cancer cell lines with ARID1A knockdown in culture (PMID: 35852858). | 35852858 |
ARID1A inact mut | urinary bladder cancer | sensitive | CPI-1205 | Preclinical - Cell culture | Actionable | In a preclinical study, CPI-1205 inhibited viability of bladder cancer cell lines harboring ARID1A inactivating mutations in culture (PMID: 35852858). | 35852858 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02395601 | Phase I | CPI-1205 | A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas | Completed | USA | 0 |